Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Listed
Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,163 across all filing types
Latest filing 2026-06-19 Regulatory Filings
Country AU Australia
Listing ASX 1AI · 3 venues

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Cleansing Notice 1 page 152.2KB
Regulatory Filings Classification · 95% confidence The document is titled as an ASX Announcement by Algorae Pharmaceuticals and is a Section 708A(5)(e) Cleansing Notice under the Corporations Act 2001 (Cth). This type of notice confirms the issuance of shares without disclosure under part of the Act and compliance with certain sections of the law. The document is brief (1314 characters) and serves as a formal regulatory communication rather than a detailed report or a financial statement. There is no financial data, earnings information, or detailed report content here. It is mainly an official statement connected to capital issuance compliance. Given the content and length, this fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document, and not under categories like Capital/Financing Update which would focus more on financial details of the capital transaction.
2026-06-19 English
Application for quotation of securities - 1AI 6 pages 18.1KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an official announcement to the ASX regarding securities to be quoted following the exercise of options/conversion of convertible securities. It provides detailed information about the securities issued, the numbers, issue dates, and other required details for quoting on the exchange. It does not include financial results, earnings data, or management commentary, nor is it an annual or quarterly report. This document is clearly related to capital changes, specifically the issuing and quoting of new shares due to option exercises. Therefore, it fits the 'Share Issue/Capital Change' category.
2026-06-19 English
Application for quotation of securities - 1AI 6 pages 18.2KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and includes details about the application to list new securities on the ASX (Australian Securities Exchange). It specifies the securities, issue date, pricing, and distribution schedule. It references a prior Appendix 3B announcement for the security issuance. The content is an official application form for ASX listing of securities, which falls under announcements about share issuance or capital structure changes rather than financial performance or management reports. There are no financial statements or detailed financial analysis present. Hence, this document is best classified under Share Issue/Capital Change (SHA), which includes announcements regarding new share issues and related capital changes.
2026-06-19 English
Proposed issue of securities - 1AI 5 pages 17.1KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and details a placement or other type of securities issue by ALGORA PHARMACEUTICALS LIMITED. It provides specifics about the number of shares to be issued, issue price, dates, approval status, and related conditions. The document is an announcement related to the company's capital structure change, specifically the issuing of new shares (placement). There are no financial statements, financial performance, or regulatory certifications. This is a capital/financing update type of document, and given that the text matches a standard ASX Appendix 3B form for securities issuance, the classification is Capital/Financing Update (CAP).
2026-06-16 English
Application for quotation of securities - 1AI 7 pages 20.8KB
Share Issue/Capital Change Classification · 92% confidence The document is the ASX Appendix 2A “Application for quotation of securities” detailing the issuance and quotation of 500,000 new shares under an employee incentive plan. This is a capital change announcement (new share issue/quotation) rather than a full financial report or regulatory certification. It fits the Share Issue/Capital Change category.
2026-05-24 English
Notification regarding unquoted securities - 1AI 6 pages 18.4KB
Share Issue/Capital Change Classification · 97% confidence The document is an ASX Appendix 3G notification of the issue/conversion of unquoted equity securities (performance rights) under an employee incentive scheme. It details the number of securities issued, dates, and listing rule references. This is clearly an announcement of a share issuance/capital change, matching the definition for Share Issue/Capital Change (Code: SHA).
2026-05-24 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.